C4 Therapeutics Inc (CCCC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.76+0.53%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CCCC
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 35.0 | 35.9 | 35.6 | 20.8 | 31.1 | 45.8 | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 100.0 | 104.2 | 110.6 | 117.7 | 117.8 | 94.7 | 78.4 |
| Operating Income | (111.8) | (115.2) | (119.6) | (139.0) | (129.5) | (82.1) | (60.4) |
| Earnings from Continuing Operations | |||||||
| Other Non-Operating Income / Expenses | 10.5 | 10.3 | 14.4 | 7.8 | 1.4 | (1.8) | (6.5) |
| EBT, Incl. Unusual Items | — | (104.9) | (105.2) | (131.2) | (128.2) | (83.9) | (67.0) |
| Income Tax Expense | — | 0.1 | 0.1 | 1.3 | 0.0 | 0.0 | (0.6) |
| Net Income | |||||||
| Net Income | (101.4) | (105.0) | (105.3) | (132.5) | (128.2) | (83.9) | (66.3) |
| Per Share | |||||||
| Basic EPS | (0.78) | (1.27) | (1.52) | (2.67) | (2.62) | (1.82) | (5.83) |
| Diluted EPS | (0.78) | (1.27) | (1.52) | (2.67) | (2.62) | (1.82) | — |
| Revenue per Share | 0.27 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 130.7 | 82.9 | 69.4 | 49.6 | 48.9 | 46.0 | — |
| Diluted Weighted Avg Shares | 130.7 | 82.9 | 69.4 | 49.6 | 48.9 | 46.0 | — |
| Supplemental | |||||||
| EBITDA | — | (113.3) | (117.8) | (137.2) | (127.9) | (80.6) | (58.8) |
| EBIT | (111.8) | (115.2) | (119.6) | (139.0) | (129.5) | (82.1) | (60.4) |
| Effective Tax Rate | — | — | — | -1.0% | 0.0% | 0.0% | 0.9% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.